These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 33628593)

  • 21. Zebrafish patient-derived xenograft models predict lymph node involvement and treatment outcome in non-small cell lung cancer.
    Ali Z; Vildevall M; Rodriguez GV; Tandiono D; Vamvakaris I; Evangelou G; Lolas G; Syrigos KN; Villanueva A; Wick M; Omar S; Erkstam A; Schueler J; Fahlgren A; Jensen LD
    J Exp Clin Cancer Res; 2022 Feb; 41(1):58. PubMed ID: 35139880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kinomic profiling of tumour xenografts derived from patients with non-small cell lung cancer confirms their fidelity and reveals potentially actionable pathways.
    Tabbò F; Guerrera F; van den Berg A; Gaudiano M; Maletta F; Bessone L; Nottegar A; Costardi L; de Wijn R; Ruijtenbeek R; Delsedime L; Sapino A; Ruffini E; Hilhorst R; Inghirami G
    Eur J Cancer; 2021 Feb; 144():17-30. PubMed ID: 33316635
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non-Small Cell Lung Cancer.
    Woo XY; Srivastava A; Mack PC; Graber JH; Sanderson BJ; Lloyd MW; Chen M; Domanskyi S; Gandour-Edwards R; Tsai RA; Keck J; Cheng M; Bundy M; Jocoy EL; Riess JW; Holland W; Grubb SC; Peterson JG; Stafford GA; Paisie C; Neuhauser SB; Karuturi RKM; George J; Simons AK; Chavaree M; Tepper CG; Goodwin N; Airhart SD; Lara PN; Openshaw TH; Liu ET; Gandara DR; Bult CJ
    Cancer Res; 2022 Nov; 82(22):4126-4138. PubMed ID: 36069866
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform.
    Gandara DR; Mack PC; Bult C; Li T; Lara PN; Riess JW; Astrow SH; Gandour-Edwards R; Cooke DT; Yoneda KY; Moore EH; Pan CX; Burich RA; David EA; Keck JG; Airhart S; Goodwin N; de Vere White RW; Liu ET
    Clin Lung Cancer; 2015 May; 16(3):165-72. PubMed ID: 25838158
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy.
    Dong X; Guan J; English JC; Flint J; Yee J; Evans K; Murray N; Macaulay C; Ng RT; Gout PW; Lam WL; Laskin J; Ling V; Lam S; Wang Y
    Clin Cancer Res; 2010 Mar; 16(5):1442-51. PubMed ID: 20179238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative Study on the Efficacy and Exposure of Molecular Target Agents in Non-small Cell Lung Cancer PDX Models with Driver Genetic Alterations.
    Jo H; Yagishita S; Hayashi Y; Ryu S; Suzuki M; Kohsaka S; Ueno T; Matsumoto Y; Horinouchi H; Ohe Y; Watanabe SI; Motoi N; Yatabe Y; Mano H; Takahashi K; Hamada A
    Mol Cancer Ther; 2022 Feb; 21(2):359-370. PubMed ID: 34911818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-Derived Xenograft Models for Translational Prostate Cancer Research and Drug Development.
    Philp LK
    Methods Mol Biol; 2024; 2806():153-185. PubMed ID: 38676802
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies.
    Liu L; Wu M; Huang A; Gao C; Yang Y; Liu H; Jiang H; Yu L; Huang Y; Wang H
    J Transl Med; 2023 Sep; 21(1):611. PubMed ID: 37689699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
    Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
    Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non-small cell lung cancer.
    John T; Kohler D; Pintilie M; Yanagawa N; Pham NA; Li M; Panchal D; Hui F; Meng F; Shepherd FA; Tsao MS
    Clin Cancer Res; 2011 Jan; 17(1):134-41. PubMed ID: 21081655
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumorigenic circulating tumor cells from xenograft mouse models of non-metastatic NSCLC patients reveal distinct single cell heterogeneity and drug responses.
    Suvilesh KN; Nussbaum YI; Radhakrishnan V; Manjunath Y; Avella DM; Staveley-O'Carroll KF; Kimchi ET; Chaudhuri AA; Shyu CR; Li G; Pantel K; Warren WC; Mitchem JB; Kaifi JT
    Mol Cancer; 2022 Mar; 21(1):73. PubMed ID: 35279152
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.
    Drapkin BJ; George J; Christensen CL; Mino-Kenudson M; Dries R; Sundaresan T; Phat S; Myers DT; Zhong J; Igo P; Hazar-Rethinam MH; Licausi JA; Gomez-Caraballo M; Kem M; Jani KN; Azimi R; Abedpour N; Menon R; Lakis S; Heist RS; Büttner R; Haas S; Sequist LV; Shaw AT; Wong KK; Hata AN; Toner M; Maheswaran S; Haber DA; Peifer M; Dyson N; Thomas RK; Farago AF
    Cancer Discov; 2018 May; 8(5):600-615. PubMed ID: 29483136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune cell infiltration pattern in non-small cell lung cancer PDX models is a model immanent feature and correlates with a distinct molecular and phenotypic make-up.
    Oswald E; Bug D; Grote A; Lashuk K; Bouteldja N; Lenhard D; Löhr A; Behnke A; Knauff V; Edinger A; Klingner K; Gaedicke S; Niedermann G; Merhof D; Feuerhake F; Schueler J
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35483746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts.
    Rolff J; Becker M; Merk J; Hoffmann J; Fichtner I
    Target Oncol; 2016 Aug; 11(4):507-14. PubMed ID: 26817645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Establishment and characterization of a non-gestational choriocarcinoma patient-derived xenograft model.
    Oda Y; Niimi K; Yoshida K; Tamauchi S; Yokoi A; Yasui Y; Nishiko Y; Shibata M; Shimizu Y; Yoshihara M; Ikeda Y; Yoshikawa N; Nishino K; Yamamoto E; Kajiyama H
    BMC Cancer; 2023 Nov; 23(1):1103. PubMed ID: 37957624
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Establishment of Novel Gastric Cancer Patient-Derived Xenografts and Cell Lines: Pathological Comparison between Primary Tumor, Patient-Derived, and Cell-Line Derived Xenografts.
    Kuwata T; Yanagihara K; Iino Y; Komatsu T; Ochiai A; Sekine S; Taniguchi H; Katai H; Kinoshita T; Ohtsu A
    Cells; 2019 Jun; 8(6):. PubMed ID: 31207870
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FGFR1 overexpression in non-small cell lung cancer is mediated by genetic and epigenetic mechanisms and is a determinant of FGFR1 inhibitor response.
    Bogatyrova O; Mattsson JSM; Ross EM; Sanderson MP; Backman M; Botling J; Brunnström H; Kurppa P; La Fleur L; Strell C; Wilm C; Zimmermann A; Esdar C; Micke P
    Eur J Cancer; 2021 Jul; 151():136-149. PubMed ID: 33984662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
    Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
    Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of Patient-Derived Xenograft Formation and Clinical Significance of Programmed Cell Death Ligand 1 (PD-L1) in Lung Cancer Patients.
    Ma Y; Zhang P; An G; Zhang X; Zhang L; Si J; Zhang J; Yang Y
    Med Sci Monit; 2016 Oct; 22():4017-4025. PubMed ID: 27784882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.